Overview

XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This multicenter observational study will evaluate the efficacy and safety of Xeloda (capecitabine) in combination with docetaxel in first-line therapy in participants with HER2-negative metastatic breast cancer. Participants will be followed for approximately 6 months of treatment.
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Capecitabine
Docetaxel